Nordic Nanovector supports The Health Policy Partnership’s initiative to improve appropriate readiness for radioligand therapy (radioimmunotherapy) in lymphoma
Abstract by The Health Policy Partnership entitled “System-Level Barriers to Uptake of Existing and Novel Radioimmunotherapy for People with Lymphoma” will be presented at the 63[rd] ASH Annual Meeting, 11–14 December 2021Oslo, Norway, 9 November 2021 Nordic Nanovector ASA (OSE: NANOV) a clinical-stage biotechnology company dedicated to extending and improving the lives of patients with haematological cancers, is supporting an independent government affairs project led by The Health Policy Partnership (HPP), a specialist health policy research organisation. Within this project, an